| Descriptor English: | Antineoplastic Agents | ||||||
| Descriptor Spanish: |
Antineoplásicos
| ||||||
| Descriptor Portuguese: | Antineoplásicos | ||||||
| Descriptor French: | Antinéoplasiques | ||||||
| Entry term(s): |
Agent, Anticancer Agent, Antineoplastic Agent, Antitumor Agent, Cancer Chemotherapy Agents, Anticancer Agents, Antineoplastic Agents, Antitumor Agents, Cancer Chemotherapy Agents, Chemotherapeutic Anticancer Anticancer Agent Anticancer Agents Antineoplastic Antineoplastic Agent Antineoplastic Drug Antineoplastic Drugs Antineoplastics Antitumor Agent Antitumor Agents Antitumor Drug Antitumor Drugs Cancer Chemotherapy Agent Cancer Chemotherapy Agents Cancer Chemotherapy Drug Cancer Chemotherapy Drugs Chemotherapeutic Anticancer Agents Chemotherapeutic Anticancer Drug Chemotherapy Agent, Cancer Chemotherapy Agents, Cancer Chemotherapy Drug, Cancer Chemotherapy Drugs, Cancer Drug, Antineoplastic Drug, Antitumor Drug, Cancer Chemotherapy Drug, Chemotherapeutic Anticancer Drugs, Antineoplastic Drugs, Antitumor Drugs, Cancer Chemotherapy |
||||||
| Tree number(s): |
D27.505.954.248 |
||||||
| RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D000970 | ||||||
| Scope note: | Substances that inhibit or prevent the proliferation of NEOPLASMS. |
||||||
| Annotation: | /admin: various administration procedures are available, as CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CHEMOEMBOLIZATION, THERAPEUTIC and INFUSIONS, INTRA-ARTERIAL; for combined anticancer agents, ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS is available; Manual 24.4.2.1+ |
||||||
| Allowable Qualifiers: |
AD administration & dosage AE adverse effects AN analysis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis EC economics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||||
| Entry Version: | ANTINEOPL AGENTS |
||||||
| Related: |
Anticarcinogenic Agents
MeSH Chemoembolization, Therapeutic MeSH Chemotherapy, Cancer, Regional Perfusion MeSH Cytotoxins MeSH Infusions, Intra-Arterial MeSH Tumor Lysis Syndrome MeSH | ||||||
| DeCS ID: | 974 | ||||||
| Unique ID: | D000970 | ||||||
| NLM Classification: | QV 269 | ||||||
| Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
| Date Established: | 1966/01/01 | ||||||
| Date of Entry: | 1999/01/01 | ||||||
| Revision Date: | 2020/05/27 |
-
-
CHEMICALS AND DRUGS
Chemical Actions and Uses [D27]Chemical Actions and Uses
|
|
Antineoplastic Agents
- Preferred
| Concept UI |
M0001483 |
| Scope note | Substances that inhibit or prevent the proliferation of NEOPLASMS. |
| Preferred term | Antineoplastic Agents |
| Entry term(s) |
Agent, Anticancer Agent, Antineoplastic Agent, Antitumor Agent, Cancer Chemotherapy Agents, Anticancer Agents, Antineoplastic Agents, Antitumor Agents, Cancer Chemotherapy Agents, Chemotherapeutic Anticancer Anticancer Agent Anticancer Agents Antineoplastic Antineoplastic Agent Antineoplastic Drug Antineoplastic Drugs Antineoplastics Antitumor Agent Antitumor Agents Antitumor Drug Antitumor Drugs Cancer Chemotherapy Agent Cancer Chemotherapy Agents Cancer Chemotherapy Drug Cancer Chemotherapy Drugs Chemotherapeutic Anticancer Agents Chemotherapeutic Anticancer Drug Chemotherapy Agent, Cancer Chemotherapy Agents, Cancer Chemotherapy Drug, Cancer Chemotherapy Drugs, Cancer Drug, Antineoplastic Drug, Antitumor Drug, Cancer Chemotherapy Drug, Chemotherapeutic Anticancer Drugs, Antineoplastic Drugs, Antitumor Drugs, Cancer Chemotherapy |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey
